PDCD1 and biliary tract neoplasm: Marseille-P5997) associates with improved anti-programmed cell death protein 1(PD-1) immunotherapy outcomes in biliary tract cancers (38), Proteobacteria dominance inversely correlates with Sintilimab-anlotinib combination efficacy in advanced cases (39).